Home
Amgen AMGN paid Forbes-Tate $50K for lobbying in Q2 2026 · Taxation, Medicare and 2 more issues
Trade details
- Type
- Lobbying report
- Amount
- $50,000
- Quarter
- Q2 2026
- Stock
- Amgen AMGN
- Client
- Amgen
- Reported
- 26/07/20
Down 37.5% from last quarter
What else happened in Amgen around then
Filed or reported within 30 days of the trade day · 05/31~07/30Amgen's other lobbying reports
- Amgen
LobbyingAmgen
LobbyingAmgen
AMGN
Under $5,000
Under $5,000
Reported 07/28
for Q2
- Amgen
LobbyingAmgen
LobbyingAmgen
AMGN
Under $5,000
Under $5,000
Reported 07/21
for Q2
- Amgen
LobbyingAmgen
LobbyingAmgen
AMGN
$80K
$80K
Reported 07/20
for Q2
- Amgen
LobbyingAmgen
LobbyingAmgen
AMGN
$60K
$60K
Reported 07/20
for Q2
- Amgen
LobbyingAmgen
LobbyingAmgen
AMGN
$2.4M
$2.4M
Reported 07/20
for Q2